Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

08/09/2026

✍️ 𝐒𝐚𝐯𝐞 𝐭𝐡𝐞 𝐝𝐚𝐭𝐞! 𝐖𝐞’𝐫𝐞 𝐡𝐞𝐚𝐝𝐢𝐧𝐠 𝐭𝐨 𝐄𝐂𝐏 𝟐𝟎𝟐𝟔 𝐢𝐧 𝐒𝐭𝐨𝐜𝐤𝐡𝐨𝐥𝐦!
Come meet the Biocartis team and discover the fully automated 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦, delivering in-house molecular biomarker results in only 3 hours!
📅 12-16 September
📍 Stockholm, Sweden
📌 𝐁𝐨𝐨𝐭𝐡 #𝟒𝟐𝟑

We look forward to connecting with you at the ESP European Society of Pathology Congress
𝐁𝐨𝐨𝐤 𝐚 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦🤝 https://www.biocartis.com/en/news-events/events/ecp-2026?utm_source=facebook&utm_medium=social&utm_campaign=0109_ecp-2026

03/09/2026

🎗️ During 𝐆𝐲𝐧𝐞𝐜𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, we highlight the importance of continued progress in understanding and addressing gynecological cancers, including 𝐞𝐧𝐝𝐨𝐦𝐞𝐭𝐫𝐢𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫.

𝐏𝐎𝐋𝐄 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐬𝐭𝐚𝐭𝐮𝐬 𝐚𝐧𝐝 𝐌𝐒𝐈/𝐌𝐌𝐑 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 are two of the pivotal biomarkers in the current molecular classification of endometrial cancer, which stratifies tumors into four subgroups: POLE-mutated (POLEmut), mismatch repair-deficient (MMRd), no specific molecular profile (NSMP), and p53-abnormal (p53abn).

The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲 and 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐌𝐒𝐈 𝐀𝐬𝐬𝐚𝐲 support standardized molecular profiling through a fully automated, on-demand workflow.
✔️ 17 POLE mutations and 7 MSI status biomarkers
✔️ Standardized result report in ≤ 150 min.
✔️ Fully automated molecular walk-away system for on-demand testing
✔️ Directly from FFPE with < 3 min. HoT
✔️ High concordance compared to state-of-the-art methods

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄 👉 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=0109_idylla-pole-pold1-mutation-assay
𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐌𝐒𝐈 👉 https://www.biocartis.com/en/research/research-assays/idylla-msi-assay?utm_source=facebook&utm_medium=social&utm_campaign=0109_idylla-msi-assay

Idylla™ POLE-POLD1 Mutation Assay and Idylla™ MSI Assay are for Research Use Only (RUO), not for use in diagnostic procedures.

02/09/2026

📚 𝗜𝗗𝗬𝗟𝗟𝗔™ 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗛𝗜𝗚𝗛𝗟𝗜𝗚𝗛𝗧𝗦 𝗛𝟭 𝟮𝟬𝟮𝟲: 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗮𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗳𝗿𝗼𝗺 𝗿𝗲𝘀𝗶𝗱𝘂𝗮𝗹 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝘆 𝘀𝗮𝗺𝗽𝗹𝗲𝘀
For the final post in our H1 2026 Publication Highlights series, we take a closer look at a study by Antón-Peñalver et al. (2026)* evaluated the use of the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗠𝗦𝗜 𝗔𝘀𝘀𝗮𝘆** on residual liquid-based cytology (LBC) samples from EUS-FNA specimens in pancreatic cancer.

💡𝗦𝘁𝘂𝗱𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- 268 patients, with Idylla™ MSI testing performed on 38 available residual samples
- 95.7% of residual LBC samples and 86.7% of cell block samples generated valid results
- No significant difference in validity between sample types

The findings demonstrate how 𝗿𝗲𝘀𝗶𝗱𝘂𝗮𝗹 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝘆 𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝗰𝗮𝗻 𝗵𝗲𝗹𝗽 𝗽𝗿𝗲𝘀𝗲𝗿𝘃𝗲 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴, even when cell block material is limited or unavailable.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/eFXsf8up

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗠𝗦𝗜 𝗔𝘀𝘀𝗮𝘆: https://lnkd.in/eNG37C56

* Antón-Peñalver, R. et al. (2026). Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples. Cytopathology, 37(3), 275–283. https://lnkd.in/eEgf7TcK
** For Research Use Only (RUO), not for use in diagnostic procedures.

01/09/2026

🩸September is 𝐁𝐥𝐨𝐨𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, a month in which we raise awareness on blood cancer - its types, signs, symptoms & impact - and give it the attention it needs!

🤔 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐭𝐡𝐚𝐭...
- Acute Myeloid Leukemia (AML) is a rare type of blood cancer
- IDH1 and IDH2 biomarkers are detected in 20% of AML cases
- Our Idylla™ IDH1-2 Mutation Assay Kit (RUO*) can detect 5 mutations in the IDH1 gene and 10 mutations in the IDH2 gene

👉 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://www.biocartis.com/en/research/research-assays/idylla-idh1-2-mutation-assay-kit?utm_source=facebook&utm_medium=social&utm_campaign=idylla-idh1-2-mutation-assay-kit

*For Research Use Only (RUO), not for use in diagnostic procedures.

27/08/2026

✍️ 𝗦𝗮𝘃𝗲 𝘁𝗵𝗲 𝗱𝗮𝘁𝗲! 𝗪𝗲’𝗿𝗲 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗘𝗖𝗣 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗦𝘁𝗼𝗰𝗸𝗵𝗼𝗹𝗺!
Come meet the Biocartis team and discover the fully automated 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺, delivering in-house molecular biomarker results in only 3 hours!
📅 12-16 September
📍 Stockholm, Sweden
📌 𝗕𝗼𝗼𝘁𝗵 #𝟰𝟮𝟯

We look forward to connecting with you at the European Congress of Pathology!
𝗕𝗼𝗼𝗸 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺🤝 https://www.biocartis.com/en/news-events/events/ecp-2026

26/08/2026

📚 𝗜𝗗𝗬𝗟𝗟𝗔™ 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗛𝗜𝗚𝗛𝗟𝗜𝗚𝗛𝗧𝗦 𝗛𝟭 𝟮𝟬𝟮𝟲: 𝗥𝗮𝗽𝗶𝗱 𝗡𝗧𝗥𝗞 𝗳𝘂𝘀𝗶𝗼𝗻 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝘂𝗺𝗼𝗿 𝘁𝘆𝗽𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗚𝗲𝗻𝗲𝗙𝘂𝘀𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆*
As part of our H1 2026 Publication Highlight series, we take a closer look at a study by Sura et al. (2026)** that evaluates the Idylla™ GeneFusion Assay for NTRK1/2/3 detection in a pan-cancer, fusion-enriched cohort from two US academic centers.

💡𝗦𝘁𝘂𝗱𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- 193 samples evaluated across thyroid cancer, NSCLC, breast cancer, colorectal cancer, pancreatic cancer, and other tumor types
- 95.7% PPA and 100% NPA for unequivocal calls vs. NGS
- NTRK results in only 3 hours with < 3 minutes hands-on time

The study represents one of the largest published NTRK-positive validation cohorts and highlights the potential of 𝗿𝗮𝗽𝗶𝗱, 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗯𝗿𝗼𝗮𝗱 𝗽𝗮𝗻-𝘁𝘂𝗺𝗼𝗿 𝗡𝗧𝗥𝗞 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗯𝗲𝗳𝗼𝗿𝗲 𝗰𝗼𝗻𝗳𝗶𝗿𝗺𝗮𝘁𝗼𝗿𝘆 𝗡𝗚𝗦.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://pubmed.ncbi.nlm.nih.gov/42320753/

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗚𝗲𝗻𝗲𝗙𝘂𝘀𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆: https://www.biocartis.com/en/research/research-assays/idylla-genefusion-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
** Sura, G. H. et al. (2026). Validation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-Based PCR Assay. The Journal of Molecular Diagnostics : JMD, S1525-1578(26)00105-4. https://doi.org/10.1016/j.jmoldx.2026.06.002

25/08/2026

💡𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗮𝗸𝗲 𝘁𝗼 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀?
Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds, UK) explores this question in our on-demand webinar, highlighting why reliable MSI testing remains critical for identifying the right patients for immunotherapy.

𝗔 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆: "𝘐𝘯 𝘵𝘩𝘦 𝘊𝘩𝘦𝘤𝘬𝘔𝘢𝘵𝘦 8𝘏𝘞 𝘵𝘳𝘪𝘢𝘭, 17% 𝘰𝘧 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘥 𝘢𝘴 𝘥𝘔𝘔𝘙/𝘔𝘚𝘐-𝘏 𝘣𝘺 𝘭𝘰𝘤𝘢𝘭 𝘵𝘦𝘴𝘵𝘪𝘯𝘨 𝘸𝘦𝘳𝘦 𝘳𝘦𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘥 𝘢𝘴 𝘔𝘚𝘚 𝘰𝘯 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘳𝘦𝘵𝘦𝘴𝘵𝘪𝘯𝘨 𝘣𝘺 𝘐𝘥𝘺𝘭𝘭𝘢™. 𝘉𝘶𝘵 𝘸𝘩𝘢𝘵 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘥𝘪𝘥 𝘵𝘩𝘢𝘵 𝘮𝘢𝘬𝘦 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴? 𝘞𝘩𝘦𝘯 𝘵𝘩𝘦 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘸𝘢𝘴 𝘳𝘦𝘧𝘪𝘯𝘦𝘥 𝘵𝘰 𝘵𝘳𝘶𝘭𝘺 𝘔𝘚𝘐-𝘏 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴, 𝘵𝘩𝘦 𝘰𝘣𝘫𝘦𝘤𝘵𝘪𝘷𝘦 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘳𝘢𝘵𝘦 𝘸𝘢𝘴 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘩𝘪𝘨𝘩𝘦𝘳. 𝘛𝘩𝘪𝘴 𝘵𝘦𝘭𝘭𝘴 𝘶𝘴 𝘸𝘦 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘸𝘩𝘦𝘳𝘦 𝘸𝘦 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘣𝘦 𝘸𝘪𝘵𝘩 𝘢𝘤𝘤𝘶𝘳𝘢𝘵𝘦 𝘵𝘦𝘴𝘵𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘵𝘩𝘢𝘵 𝘨𝘢𝘱 𝘩𝘢𝘴 𝘳𝘦𝘢𝘭 𝘤𝘰𝘯𝘴𝘦𝘲𝘶𝘦𝘯𝘤𝘦𝘴 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘯𝘥 𝘵𝘩𝘦𝘪𝘳 𝘧𝘪𝘳𝘴𝘵-𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴."

In the webinar, Professor Seligmann also explores:
✔️ Updates to the ESMO mCRC guidelines
✔️ Dual IHC/molecular testing for immunotherapy eligibility
✔️ Emerging biomarker testing strategies in early-stage disease

🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://lnkd.in/eS4p5wfX

Idylla™ CDx MSI Test (A0220/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and approved in the US under P250005.

21/08/2026

𝐀𝐫𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐠𝐚𝐩𝐬 𝐥𝐢𝐦𝐢𝐭𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐝𝐫𝐮𝐠’𝐬 𝐫𝐞𝐚𝐜𝐡 𝐢𝐧 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲?
Our Idylla™ Platform can help close these gaps.

Idylla™ is a fully automated molecular testing platform with 3 hours TAT, few invalid results, suitable for any lab and a global reach.

Partnering with Biocartis means we develop Idylla™ tests that identify the right biomarkers in your drug’s target population — and ensure those tests are accessible wherever your drug needs to reach, closing multiple diagnostic gaps along the way.

Let’s find your entry point → [email protected]

19/08/2026

📚 𝗜𝗗𝗬𝗟𝗟𝗔™ 𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗛𝗜𝗚𝗛𝗟𝗜𝗚𝗛𝗧𝗦 𝗛𝟭 𝟮𝟬𝟮𝟲: 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗜𝗗𝗛 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗯𝗲𝘆𝗼𝗻𝗱 𝗴𝗹𝗶𝗼𝗺𝗮 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗜𝗗𝗛𝟭-𝟮 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 𝗞𝗶𝘁*
Continuing our H1 2026 Idylla™ Publication Highlights series, we take a closer look at a study by Gilson et al. (2026)** that evaluates the performance of the Idylla™ IDH1-2 Mutation Assay Kit across a range of IDH-driven tumor types (including glioma, cholangiocarcinoma, chondrosarcoma, breast cancer and AML).

💡𝗦𝘁𝘂𝗱𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- 106 samples evaluated across diverse IDH-mutated tumor types
- 97.1% OPA, 98.0% PPV and 96.2% NPV vs. NGS
- Detection limits down to 1.6% for IDH1 R132H and 0.5% for IDH2 R172K
- IDH results in only 95 minutes

These findings highlight the Idylla™ IDH1-2 Mutation Assay Kit as a 𝗿𝗮𝗽𝗶𝗱 𝗽𝗿𝗲-𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝘁𝗼𝗼𝗹 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗜𝗗𝗛-𝗺𝘂𝘁𝗮𝘁𝗲𝗱 𝘁𝘂𝗺𝗼𝗿 𝘁𝘆𝗽𝗲𝘀.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://pubmed.ncbi.nlm.nih.gov/41596663/

👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗜𝗗𝗛𝟭-𝟮 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 𝗞𝗶𝘁: https://www.biocartis.com/en/research/research-assays/idylla-idh1-2-mutation-assay-kit

* For Research Use Only (RUO), not for use in diagnostic procedures.
**Gilson, P. et al. (2026). Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies. International Journal of Molecular Sciences, 27(2), 1017. https://doi.org/10.3390/ijms27021017

18/08/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, with results in only three hours. Ensure they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2026-03/CRC%20Oncologist%20-%20Leaflet%20-%20Mar2026.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
The content of this post is only applicable to Idylla™ KRAS & NRAS-BRAF Mutation Tests and Idylla™ MSI & CDx MSI Tests which are CE-marked in Europe; Idylla™ MSI Test which is cleared in the US under K211181 for Lynch Syndrome; and Idylla™ CDx MSI Test which is approved in the US under P250005. Idylla™ KRAS & NRAS-BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.